TCM
AZN icon

TimesSquare Capital Management’s AstraZeneca AZN Stock Holding History

TimesSquare Capital Management’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-65,165
Closed -$4.58M – 236
2018
Q2 		$4.58M Buy
65,165
+2,500
+4% +$180K 0.03% 234
2018
Q1 		$4.38M Buy
62,665
+13,295
+27% +$921K 0.03% 236
2017
Q4 		$3.43M Buy
49,370
+11,257
+30% +$759K 0.02% 235
2017
Q3 		$2.58M Buy
+38,113
New +$2.41M 0.02% 242

Other funds holding AZN

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
EIP
Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return

TimesSquare Capital Management's AZN Position: Q3 2018 in Review

TimesSquare Capital Management sold out of AstraZeneca (AZN) in Q3 2018, closing a stake of 65,165 shares — an estimated $4.58M sold.

TimesSquare Capital Management first reported a position in AZN in Q3 2017 and held it in 4 quarters. The position peaked at $4.58M in Q2 2018. 544 funds tracked by Wall St. Rank hold AZN as of Q3 2018.

  • TimesSquare Capital Management reported no remaining AstraZeneca position as of Q3 2018 after selling out during the quarter.
  • TimesSquare Capital Management sold 65,165 AstraZeneca shares in Q3 2018, an estimated $4.58M.
  • TimesSquare Capital Management first reported a position in AstraZeneca in Q3 2017 and held it in 4 quarters.
  • TimesSquare Capital Management's AstraZeneca position peaked at $4.58M in Q2 2018.
  • 544 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2018.

Based on TimesSquare Capital Management's 13F filing for Q3 2018, filed 14 Nov 2018.